Fidelity Investments
AVBP icon

Fidelity Investments’s ArriVent BioPharma AVBP Stock Holding History

Fidelity Investments’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.6M Sell
3,016,132
-687,440
-19% -$15.5M ﹤0.01% 1315
2025
Q4 		$74.5M Buy
3,703,572
+296,023
+9% +$6.16M ﹤0.01% 1291
2025
Q3 		$62.9M Buy
3,407,549
+1,349,480
+66% +$26.5M ﹤0.01% 1360
2025
Q2 		$44.8M Sell
2,058,069
-20,590
-1% -$428K ﹤0.01% 1440
2025
Q1 		$38.4M Sell
2,078,659
-22,378
-1% -$548K ﹤0.01% 1453
2024
Q4 		$56M Sell
2,101,037
-18,658
-0.9% -$536K ﹤0.01% 1340
2024
Q3 		$49.8M Buy
2,119,695
+169,514
+9% +$3.85M ﹤0.01% 1373
2024
Q2 		$36.2M Buy
1,950,181
+147
+0% +$2.62K ﹤0.01% 1436
2024
Q1 		$34.8M Buy
+1,950,034
New +$39.3M ﹤0.01% 1466

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Fidelity Investments's AVBP Position: Q1 2026 in Review

Fidelity Investments reduced its ArriVent BioPharma (AVBP) stake by 19% in Q1 2026, selling an estimated $15.5M and leaving 3,016,132 shares worth $69.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Fidelity Investments first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $74.5M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Fidelity Investments held 3,016,132 shares of ArriVent BioPharma worth $69.6M as of Q1 2026.
  • Fidelity Investments sold 687,440 ArriVent BioPharma shares in Q1 2026, an estimated $15.5M.
  • ArriVent BioPharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1315 holding.
  • Fidelity Investments first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Fidelity Investments's ArriVent BioPharma position peaked at $74.5M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.